CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first-line treatment for advanced NSCLC

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Ensuring quality care for breast cancer patients globally

Teclistamab for patients with heavily pretreated relapsed or refractory multiple myeloma

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-stage small-cell lung cancer

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chemotherapy in advanced urothelial carcinoma

Better genetic diagnostics in Ugandan breast cancer patients

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associated breast cancer

Update from KAITLIN for high-risk HER2-positive early breast cancer

Sym015 shows superior specificity compared to TKIs for NSCLC

Brigatinib for NSCLC, latest research and overcoming complications

COVID-19: Treating breast cancer and the knock on effects of the coronavirus pandemic